Question: What is the length of time of market exclusivity of an orphan drug?

Answer: seven years

There are special rules for certain rare diseases ("orphan diseases") in several major drug regulatory territories. For example, diseases involving fewer than 200,000 patients in the United States, or larger populations in certain circumstances are subject to the Orphan Drug Act. <hl> Because medical research and development of drugs to treat such diseases is financially disadvantageous, companies that do so are rewarded with tax reductions, fee waivers, and market exclusivity on that drug for a limited time ( seven years ), regardless of whether the drug is protected by patents. <hl>

There are special rules for certain rare diseases ("orphan diseases") in several major drug regulatory territories. For example, diseases involving fewer than 200,000 patients in the United States, or larger populations in certain circumstances are subject to the Orphan Drug Act. Because medical research and development of drugs to treat such diseases is financially disadvantageous, companies that do so are rewarded with tax reductions, fee waivers, and market exclusivity on that drug for a limited time (<hl> seven years <hl>), regardless of whether the drug is protected by patents.

Because medical research and development of drugs to treat such diseases is financially disadvantageous, companies that do so are rewarded with tax reductions, fee waivers, and market exclusivity on that drug for a limited time ( <hl> seven years <hl> ), regardless of whether the drug is protected by patents.


Question: What is a term for rare diseases in some territories?

There are special rules for certain rare diseases ("orphan diseases") in several major drug regulatory territories. For example, diseases involving fewer than 200,000 patients in the United States, or larger populations in certain circumstances are subject to the Orphan Drug Act. Because medical research and development of drugs to treat such diseases is financially disadvantageous, companies that do so are rewarded with tax reductions, fee waivers, and market exclusivity on that drug for a limited time (seven years), regardless of whether the drug is protected by patents.

Answer: orphan diseases

<hl> There are special rules for certain rare diseases (" orphan diseases ") in several major drug regulatory territories. <hl> For example, diseases involving fewer than 200,000 patients in the United States, or larger populations in certain circumstances are subject to the Orphan Drug Act. Because medical research and development of drugs to treat such diseases is financially disadvantageous, companies that do so are rewarded with tax reductions, fee waivers, and market exclusivity on that drug for a limited time (seven years), regardless of whether the drug is protected by patents.

There are special rules for certain rare diseases ("<hl> orphan diseases <hl>") in several major drug regulatory territories. For example, diseases involving fewer than 200,000 patients in the United States, or larger populations in certain circumstances are subject to the Orphan Drug Act. Because medical research and development of drugs to treat such diseases is financially disadvantageous, companies that do so are rewarded with tax reductions, fee waivers, and market exclusivity on that drug for a limited time (seven years), regardless of whether the drug is protected by patents.

There are special rules for certain rare diseases (" <hl> orphan diseases <hl> ") in several major drug regulatory territories.


Question: Who argued against regulators?

Ben Goldacre has argued that regulators – such as the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK, or the Food and Drug Administration (FDA) in the United States – advance the interests of the drug companies rather than the interests of the public due to revolving door exchange of employees between the regulator and the companies and friendships develop between regulator and company employees. He argues that regulators do not require that new drugs offer an improvement over what is already available, or even that they be particularly effective.

Answer: Ben Goldacre

<hl> Ben Goldacre has argued that regulators – such as the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK, or the Food and Drug Administration (FDA) in the United States – advance the interests of the drug companies rather than the interests of the public due to revolving door exchange of employees between the regulator and the companies and friendships develop between regulator and company employees. <hl> He argues that regulators do not require that new drugs offer an improvement over what is already available, or even that they be particularly effective.

<hl> Ben Goldacre <hl> has argued that regulators – such as the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK, or the Food and Drug Administration (FDA) in the United States – advance the interests of the drug companies rather than the interests of the public due to revolving door exchange of employees between the regulator and the companies and friendships develop between regulator and company employees. He argues that regulators do not require that new drugs offer an improvement over what is already available, or even that they be particularly effective.


Question: Who argued that drug regulators were greater serving the interests of the drug companies than the patients?

Answer: Ben Goldacre

<hl> Ben Goldacre has argued that regulators – such as the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK, or the Food and Drug Administration (FDA) in the United States – advance the interests of the drug companies rather than the interests of the public due to revolving door exchange of employees between the regulator and the companies and friendships develop between regulator and company employees. <hl> He argues that regulators do not require that new drugs offer an improvement over what is already available, or even that they be particularly effective.

<hl> Ben Goldacre <hl> has argued that regulators – such as the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK, or the Food and Drug Administration (FDA) in the United States – advance the interests of the drug companies rather than the interests of the public due to revolving door exchange of employees between the regulator and the companies and friendships develop between regulator and company employees. He argues that regulators do not require that new drugs offer an improvement over what is already available, or even that they be particularly effective.


Question: The business friendships between which parties have been criticized?

Answer: regulator and company employees

<hl> Ben Goldacre has argued that regulators – such as the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK, or the Food and Drug Administration (FDA) in the United States – advance the interests of the drug companies rather than the interests of the public due to revolving door exchange of employees between the regulator and the companies and friendships develop between regulator and company employees . <hl> He argues that regulators do not require that new drugs offer an improvement over what is already available, or even that they be particularly effective.

Ben Goldacre has argued that regulators – such as the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK, or the Food and Drug Administration (FDA) in the United States – advance the interests of the drug companies rather than the interests of the public due to revolving door exchange of employees between the regulator and the companies and friendships develop between <hl> regulator and company employees <hl>. He argues that regulators do not require that new drugs offer an improvement over what is already available, or even that they be particularly effective.

Ben Goldacre has argued that regulators – such as the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK, or the Food and Drug Administration (FDA) in the United States – advance the interests of the drug companies rather than the interests of the public due to revolving door exchange of employees between the regulator and the companies and friendships develop between <hl> regulator and company employees <hl> .


Question: Goldacre argued that which party didn't require that new drugs be improved at all?

Answer: regulators

<hl> Ben Goldacre has argued that regulators – such as the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK, or the Food and Drug Administration (FDA) in the United States – advance the interests of the drug companies rather than the interests of the public due to revolving door exchange of employees between the regulator and the companies and friendships develop between regulator and company employees. <hl> He argues that regulators do not require that new drugs offer an improvement over what is already available, or even that they be particularly effective.

Ben Goldacre has argued that <hl> regulators <hl> – such as the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK, or the Food and Drug Administration (FDA) in the United States – advance the interests of the drug companies rather than the interests of the public due to revolving door exchange of employees between the regulator and the companies and friendships develop between regulator and company employees. He argues that regulators do not require that new drugs offer an improvement over what is already available, or even that they be particularly effective.


Question: NICE decides the availability of drugs in which two countries?

In many non-US western countries a 'fourth hurdle' of cost effectiveness analysis has developed before new technologies can be provided. This focuses on the efficiency (in terms of the cost per QALY) of the technologies in question rather than their efficacy. In England and Wales NICE decides whether and in what circumstances drugs and technologies will be made available by the NHS, whilst similar arrangements exist with the Scottish Medicines Consortium in Scotland, and the Pharmaceutical Benefits Advisory Committee in Australia. A product must pass the threshold for cost-effectiveness if it is to be approved. Treatments must represent 'value for money' and a net benefit to society.

Answer: England and Wales

In many non-US western countries a 'fourth hurdle' of cost effectiveness analysis has developed before new technologies can be provided. This focuses on the efficiency (in terms of the cost per QALY) of the technologies in question rather than their efficacy. <hl> In England and Wales NICE decides whether and in what circumstances drugs and technologies will be made available by the NHS, whilst similar arrangements exist with the Scottish Medicines Consortium in Scotland, and the Pharmaceutical Benefits Advisory Committee in Australia. <hl> A product must pass the threshold for cost-effectiveness if it is to be approved. Treatments must represent 'value for money' and a net benefit to society.

In many non-US western countries a 'fourth hurdle' of cost effectiveness analysis has developed before new technologies can be provided. This focuses on the efficiency (in terms of the cost per QALY) of the technologies in question rather than their efficacy. In <hl> England and Wales <hl> NICE decides whether and in what circumstances drugs and technologies will be made available by the NHS, whilst similar arrangements exist with the Scottish Medicines Consortium in Scotland, and the Pharmaceutical Benefits Advisory Committee in Australia. A product must pass the threshold for cost-effectiveness if it is to be approved. Treatments must represent 'value for money' and a net benefit to society.


Question: What is the name of the organization in Scotland that decides the availability of drugs?

Answer: Scottish Medicines Consortium

In many non-US western countries a 'fourth hurdle' of cost effectiveness analysis has developed before new technologies can be provided. This focuses on the efficiency (in terms of the cost per QALY) of the technologies in question rather than their efficacy. <hl> In England and Wales NICE decides whether and in what circumstances drugs and technologies will be made available by the NHS, whilst similar arrangements exist with the Scottish Medicines Consortium in Scotland, and the Pharmaceutical Benefits Advisory Committee in Australia. <hl> A product must pass the threshold for cost-effectiveness if it is to be approved. Treatments must represent 'value for money' and a net benefit to society.

In many non-US western countries a 'fourth hurdle' of cost effectiveness analysis has developed before new technologies can be provided. This focuses on the efficiency (in terms of the cost per QALY) of the technologies in question rather than their efficacy. In England and Wales NICE decides whether and in what circumstances drugs and technologies will be made available by the NHS, whilst similar arrangements exist with the <hl> Scottish Medicines Consortium <hl> in Scotland, and the Pharmaceutical Benefits Advisory Committee in Australia. A product must pass the threshold for cost-effectiveness if it is to be approved. Treatments must represent 'value for money' and a net benefit to society.


Question: What threshold must a drug pass before it is approved?

Answer: cost-effectiveness

In many non-US western countries a 'fourth hurdle' of cost effectiveness analysis has developed before new technologies can be provided. This focuses on the efficiency (in terms of the cost per QALY) of the technologies in question rather than their efficacy. In England and Wales NICE decides whether and in what circumstances drugs and technologies will be made available by the NHS, whilst similar arrangements exist with the Scottish Medicines Consortium in Scotland, and the Pharmaceutical Benefits Advisory Committee in Australia. <hl> A product must pass the threshold for cost-effectiveness if it is to be approved. <hl> Treatments must represent 'value for money' and a net benefit to society.

In many non-US western countries a 'fourth hurdle' of cost effectiveness analysis has developed before new technologies can be provided. This focuses on the efficiency (in terms of the cost per QALY) of the technologies in question rather than their efficacy. In England and Wales NICE decides whether and in what circumstances drugs and technologies will be made available by the NHS, whilst similar arrangements exist with the Scottish Medicines Consortium in Scotland, and the Pharmaceutical Benefits Advisory Committee in Australia. A product must pass the threshold for <hl> cost-effectiveness <hl> if it is to be approved. Treatments must represent 'value for money' and a net benefit to society.


Question: How much money did the top ten bestselling drugs make in 2013?

The top ten best-selling drugs of 2013 totaled $75.6 billion in sales, with the anti-inflammatory drug Humira being the best-selling drug worldwide at $10.7 billion in sales. The second and third best selling were Enbrel and Remicade, respectively. The top three best-selling drugs in the United States in 2013 were Abilify ($6.3 billion,) Nexium ($6 billion) and Humira ($5.4 billion). The best-selling drug ever, Lipitor, averaged $13 billion annually and netted $141 billion total over its lifetime before Pfizer's patent expired in November 2011.

Answer: $75.6 billion

<hl> The top ten best-selling drugs of 2013 totaled $75.6 billion in sales, with the anti-inflammatory drug Humira being the best-selling drug worldwide at $10.7 billion in sales. <hl> The second and third best selling were Enbrel and Remicade, respectively. The top three best-selling drugs in the United States in 2013 were Abilify ($6.3 billion,) Nexium ($6 billion) and Humira ($5.4 billion). The best-selling drug ever, Lipitor, averaged $13 billion annually and netted $141 billion total over its lifetime before Pfizer's patent expired in November 2011.

The top ten best-selling drugs of 2013 totaled <hl> $75.6 billion <hl> in sales, with the anti-inflammatory drug Humira being the best-selling drug worldwide at $10.7 billion in sales. The second and third best selling were Enbrel and Remicade, respectively. The top three best-selling drugs in the United States in 2013 were Abilify ($6.3 billion,) Nexium ($6 billion) and Humira ($5.4 billion). The best-selling drug ever, Lipitor, averaged $13 billion annually and netted $141 billion total over its lifetime before Pfizer's patent expired in November 2011.


Question: What was the name of the top-selling anti-inflammatory drug in 2013?

Answer: Humira

<hl> The top ten best-selling drugs of 2013 totaled $75.6 billion in sales, with the anti-inflammatory drug Humira being the best-selling drug worldwide at $10.7 billion in sales. <hl> The second and third best selling were Enbrel and Remicade, respectively. The top three best-selling drugs in the United States in 2013 were Abilify ($6.3 billion,) Nexium ($6 billion) and Humira ($5.4 billion). The best-selling drug ever, Lipitor, averaged $13 billion annually and netted $141 billion total over its lifetime before Pfizer's patent expired in November 2011.

The top ten best-selling drugs of 2013 totaled $75.6 billion in sales, with the anti-inflammatory drug <hl> Humira <hl> being the best-selling drug worldwide at $10.7 billion in sales. The second and third best selling were Enbrel and Remicade, respectively. The top three best-selling drugs in the United States in 2013 were Abilify ($6.3 billion,) Nexium ($6 billion) and Humira ($5.4 billion). The best-selling drug ever, Lipitor, averaged $13 billion annually and netted $141 billion total over its lifetime before Pfizer's patent expired in November 2011.


Question: What was the bestselling drug in history?

Answer: Lipitor

The top ten best-selling drugs of 2013 totaled $75.6 billion in sales, with the anti-inflammatory drug Humira being the best-selling drug worldwide at $10.7 billion in sales. The second and third best selling were Enbrel and Remicade, respectively. The top three best-selling drugs in the United States in 2013 were Abilify ($6.3 billion,) Nexium ($6 billion) and Humira ($5.4 billion). <hl> The best-selling drug ever, Lipitor , averaged $13 billion annually and netted $141 billion total over its lifetime before Pfizer's patent expired in November 2011. <hl>

The top ten best-selling drugs of 2013 totaled $75.6 billion in sales, with the anti-inflammatory drug Humira being the best-selling drug worldwide at $10.7 billion in sales. The second and third best selling were Enbrel and Remicade, respectively. The top three best-selling drugs in the United States in 2013 were Abilify ($6.3 billion,) Nexium ($6 billion) and Humira ($5.4 billion). The best-selling drug ever, <hl> Lipitor <hl>, averaged $13 billion annually and netted $141 billion total over its lifetime before Pfizer's patent expired in November 2011.

The best-selling drug ever, <hl> Lipitor <hl> , averaged $13 billion annually and netted $141 billion total over its lifetime before Pfizer's patent expired in November 2011.


Question: How much money did Lipitor make before the patent expired?

Answer: $141 billion

The top ten best-selling drugs of 2013 totaled $75.6 billion in sales, with the anti-inflammatory drug Humira being the best-selling drug worldwide at $10.7 billion in sales. The second and third best selling were Enbrel and Remicade, respectively. The top three best-selling drugs in the United States in 2013 were Abilify ($6.3 billion,) Nexium ($6 billion) and Humira ($5.4 billion). <hl> The best-selling drug ever, Lipitor, averaged $13 billion annually and netted $141 billion total over its lifetime before Pfizer's patent expired in November 2011. <hl>

The top ten best-selling drugs of 2013 totaled $75.6 billion in sales, with the anti-inflammatory drug Humira being the best-selling drug worldwide at $10.7 billion in sales. The second and third best selling were Enbrel and Remicade, respectively. The top three best-selling drugs in the United States in 2013 were Abilify ($6.3 billion,) Nexium ($6 billion) and Humira ($5.4 billion). The best-selling drug ever, Lipitor, averaged $13 billion annually and netted <hl> $141 billion <hl> total over its lifetime before Pfizer's patent expired in November 2011.


Question: In what year did Pfizer's patent over Lipitor expire?

Answer: 2011

The top ten best-selling drugs of 2013 totaled $75.6 billion in sales, with the anti-inflammatory drug Humira being the best-selling drug worldwide at $10.7 billion in sales. The second and third best selling were Enbrel and Remicade, respectively. The top three best-selling drugs in the United States in 2013 were Abilify ($6.3 billion,) Nexium ($6 billion) and Humira ($5.4 billion). <hl> The best-selling drug ever, Lipitor, averaged $13 billion annually and netted $141 billion total over its lifetime before Pfizer's patent expired in November 2011 . <hl>

The top ten best-selling drugs of 2013 totaled $75.6 billion in sales, with the anti-inflammatory drug Humira being the best-selling drug worldwide at $10.7 billion in sales. The second and third best selling were Enbrel and Remicade, respectively. The top three best-selling drugs in the United States in 2013 were Abilify ($6.3 billion,) Nexium ($6 billion) and Humira ($5.4 billion). The best-selling drug ever, Lipitor, averaged $13 billion annually and netted $141 billion total over its lifetime before Pfizer's patent expired in November <hl> 2011 <hl>.

The best-selling drug ever, Lipitor, averaged $13 billion annually and netted $141 billion total over its lifetime before Pfizer's patent expired in November <hl> 2011 <hl> .


Question: How long do drug exclusivity rights usually last?

Depending on a number of considerations, a company may apply for and be granted a patent for the drug, or the process of producing the drug, granting exclusivity rights typically for about 20 years. However, only after rigorous study and testing, which takes 10 to 15 years on average, will governmental authorities grant permission for the company to market and sell the drug. Patent protection enables the owner of the patent to recover the costs of research and development through high profit margins for the branded drug. When the patent protection for the drug expires, a generic drug is usually developed and sold by a competing company. The development and approval of generics is less expensive, allowing them to be sold at a lower price. Often the owner of the branded drug will introduce a generic version before the patent expires in order to get a head start in the generic market. Restructuring has therefore become routine, driven by the patent expiration of products launched during the industry's "golden era" in the 1990s and companies' failure to develop sufficient new blockbuster products to replace lost revenues.

Answer: 20 years

<hl> Depending on a number of considerations, a company may apply for and be granted a patent for the drug, or the process of producing the drug, granting exclusivity rights typically for about 20 years . <hl> However, only after rigorous study and testing, which takes 10 to 15 years on average, will governmental authorities grant permission for the company to market and sell the drug. Patent protection enables the owner of the patent to recover the costs of research and development through high profit margins for the branded drug. When the patent protection for the drug expires, a generic drug is usually developed and sold by a competing company. The development and approval of generics is less expensive, allowing them to be sold at a lower price. Often the owner of the branded drug will introduce a generic version before the patent expires in order to get a head start in the generic market. Restructuring has therefore become routine, driven by the patent expiration of products launched during the industry's "golden era" in the 1990s and companies' failure to develop sufficient new blockbuster products to replace lost revenues.

Depending on a number of considerations, a company may apply for and be granted a patent for the drug, or the process of producing the drug, granting exclusivity rights typically for about <hl> 20 years <hl>. However, only after rigorous study and testing, which takes 10 to 15 years on average, will governmental authorities grant permission for the company to market and sell the drug. Patent protection enables the owner of the patent to recover the costs of research and development through high profit margins for the branded drug. When the patent protection for the drug expires, a generic drug is usually developed and sold by a competing company. The development and approval of generics is less expensive, allowing them to be sold at a lower price. Often the owner of the branded drug will introduce a generic version before the patent expires in order to get a head start in the generic market. Restructuring has therefore become routine, driven by the patent expiration of products launched during the industry's "golden era" in the 1990s and companies' failure to develop sufficient new blockbuster products to replace lost revenues.

Depending on a number of considerations, a company may apply for and be granted a patent for the drug, or the process of producing the drug, granting exclusivity rights typically for about <hl> 20 years <hl> .


Question: Governments grant permission to market drugs after how many years?

Answer: 10 to 15 years on average

Depending on a number of considerations, a company may apply for and be granted a patent for the drug, or the process of producing the drug, granting exclusivity rights typically for about 20 years. <hl> However, only after rigorous study and testing, which takes 10 to 15 years on average , will governmental authorities grant permission for the company to market and sell the drug. <hl> Patent protection enables the owner of the patent to recover the costs of research and development through high profit margins for the branded drug. When the patent protection for the drug expires, a generic drug is usually developed and sold by a competing company. The development and approval of generics is less expensive, allowing them to be sold at a lower price. Often the owner of the branded drug will introduce a generic version before the patent expires in order to get a head start in the generic market. Restructuring has therefore become routine, driven by the patent expiration of products launched during the industry's "golden era" in the 1990s and companies' failure to develop sufficient new blockbuster products to replace lost revenues.

Depending on a number of considerations, a company may apply for and be granted a patent for the drug, or the process of producing the drug, granting exclusivity rights typically for about 20 years. However, only after rigorous study and testing, which takes <hl> 10 to 15 years on average <hl>, will governmental authorities grant permission for the company to market and sell the drug. Patent protection enables the owner of the patent to recover the costs of research and development through high profit margins for the branded drug. When the patent protection for the drug expires, a generic drug is usually developed and sold by a competing company. The development and approval of generics is less expensive, allowing them to be sold at a lower price. Often the owner of the branded drug will introduce a generic version before the patent expires in order to get a head start in the generic market. Restructuring has therefore become routine, driven by the patent expiration of products launched during the industry's "golden era" in the 1990s and companies' failure to develop sufficient new blockbuster products to replace lost revenues.

However, only after rigorous study and testing, which takes <hl> 10 to 15 years on average <hl> , will governmental authorities grant permission for the company to market and sell the drug.


Question: What enables a drug's owner to recover R&D costs?

Answer: Patent protection

Depending on a number of considerations, a company may apply for and be granted a patent for the drug, or the process of producing the drug, granting exclusivity rights typically for about 20 years. However, only after rigorous study and testing, which takes 10 to 15 years on average, will governmental authorities grant permission for the company to market and sell the drug. <hl> Patent protection enables the owner of the patent to recover the costs of research and development through high profit margins for the branded drug. <hl> When the patent protection for the drug expires, a generic drug is usually developed and sold by a competing company. The development and approval of generics is less expensive, allowing them to be sold at a lower price. Often the owner of the branded drug will introduce a generic version before the patent expires in order to get a head start in the generic market. Restructuring has therefore become routine, driven by the patent expiration of products launched during the industry's "golden era" in the 1990s and companies' failure to develop sufficient new blockbuster products to replace lost revenues.

Depending on a number of considerations, a company may apply for and be granted a patent for the drug, or the process of producing the drug, granting exclusivity rights typically for about 20 years. However, only after rigorous study and testing, which takes 10 to 15 years on average, will governmental authorities grant permission for the company to market and sell the drug. <hl> Patent protection <hl> enables the owner of the patent to recover the costs of research and development through high profit margins for the branded drug. When the patent protection for the drug expires, a generic drug is usually developed and sold by a competing company. The development and approval of generics is less expensive, allowing them to be sold at a lower price. Often the owner of the branded drug will introduce a generic version before the patent expires in order to get a head start in the generic market. Restructuring has therefore become routine, driven by the patent expiration of products launched during the industry's "golden era" in the 1990s and companies' failure to develop sufficient new blockbuster products to replace lost revenues.


Question: What kind of drug is produced by competitors once a patent expires?

Answer: generic

Depending on a number of considerations, a company may apply for and be granted a patent for the drug, or the process of producing the drug, granting exclusivity rights typically for about 20 years. However, only after rigorous study and testing, which takes 10 to 15 years on average, will governmental authorities grant permission for the company to market and sell the drug. Patent protection enables the owner of the patent to recover the costs of research and development through high profit margins for the branded drug. <hl> When the patent protection for the drug expires, a generic drug is usually developed and sold by a competing company. <hl> The development and approval of generics is less expensive, allowing them to be sold at a lower price. Often the owner of the branded drug will introduce a generic version before the patent expires in order to get a head start in the generic market. Restructuring has therefore become routine, driven by the patent expiration of products launched during the industry's "golden era" in the 1990s and companies' failure to develop sufficient new blockbuster products to replace lost revenues.

Depending on a number of considerations, a company may apply for and be granted a patent for the drug, or the process of producing the drug, granting exclusivity rights typically for about 20 years. However, only after rigorous study and testing, which takes 10 to 15 years on average, will governmental authorities grant permission for the company to market and sell the drug. Patent protection enables the owner of the patent to recover the costs of research and development through high profit margins for the branded drug. When the patent protection for the drug expires, a <hl> generic <hl> drug is usually developed and sold by a competing company. The development and approval of generics is less expensive, allowing them to be sold at a lower price. Often the owner of the branded drug will introduce a generic version before the patent expires in order to get a head start in the generic market. Restructuring has therefore become routine, driven by the patent expiration of products launched during the industry's "golden era" in the 1990s and companies' failure to develop sufficient new blockbuster products to replace lost revenues.


Question: What decade was the pharmaceutical industry's "golden era"?

Answer: 1990s

Depending on a number of considerations, a company may apply for and be granted a patent for the drug, or the process of producing the drug, granting exclusivity rights typically for about 20 years. However, only after rigorous study and testing, which takes 10 to 15 years on average, will governmental authorities grant permission for the company to market and sell the drug. Patent protection enables the owner of the patent to recover the costs of research and development through high profit margins for the branded drug. When the patent protection for the drug expires, a generic drug is usually developed and sold by a competing company. The development and approval of generics is less expensive, allowing them to be sold at a lower price. Often the owner of the branded drug will introduce a generic version before the patent expires in order to get a head start in the generic market. <hl> Restructuring has therefore become routine, driven by the patent expiration of products launched during the industry's "golden era" in the 1990s and companies' failure to develop sufficient new blockbuster products to replace lost revenues. <hl>

Depending on a number of considerations, a company may apply for and be granted a patent for the drug, or the process of producing the drug, granting exclusivity rights typically for about 20 years. However, only after rigorous study and testing, which takes 10 to 15 years on average, will governmental authorities grant permission for the company to market and sell the drug. Patent protection enables the owner of the patent to recover the costs of research and development through high profit margins for the branded drug. When the patent protection for the drug expires, a generic drug is usually developed and sold by a competing company. The development and approval of generics is less expensive, allowing them to be sold at a lower price. Often the owner of the branded drug will introduce a generic version before the patent expires in order to get a head start in the generic market. Restructuring has therefore become routine, driven by the patent expiration of products launched during the industry's "golden era" in the <hl> 1990s <hl> and companies' failure to develop sufficient new blockbuster products to replace lost revenues.


Question: The safety and efficacy of new drugs must be approved by what organization in the US?

In the United States, new pharmaceutical products must be approved by the Food and Drug Administration (FDA) as being both safe and effective. This process generally involves submission of an Investigational New Drug filing with sufficient pre-clinical data to support proceeding with human trials. Following IND approval, three phases of progressively larger human clinical trials may be conducted. Phase I generally studies toxicity using healthy volunteers. Phase II can include pharmacokinetics and dosing in patients, and Phase III is a very large study of efficacy in the intended patient population. Following the successful completion of phase III testing, a New Drug Application is submitted to the FDA. The FDA review the data and if the product is seen as having a positive benefit-risk assessment, approval to market the product in the US is granted.

Answer: Food and Drug Administration

<hl> In the United States, new pharmaceutical products must be approved by the Food and Drug Administration (FDA) as being both safe and effective. <hl> This process generally involves submission of an Investigational New Drug filing with sufficient pre-clinical data to support proceeding with human trials. Following IND approval, three phases of progressively larger human clinical trials may be conducted. Phase I generally studies toxicity using healthy volunteers. Phase II can include pharmacokinetics and dosing in patients, and Phase III is a very large study of efficacy in the intended patient population. Following the successful completion of phase III testing, a New Drug Application is submitted to the FDA. The FDA review the data and if the product is seen as having a positive benefit-risk assessment, approval to market the product in the US is granted.

In the United States, new pharmaceutical products must be approved by the <hl> Food and Drug Administration <hl> (FDA) as being both safe and effective. This process generally involves submission of an Investigational New Drug filing with sufficient pre-clinical data to support proceeding with human trials. Following IND approval, three phases of progressively larger human clinical trials may be conducted. Phase I generally studies toxicity using healthy volunteers. Phase II can include pharmacokinetics and dosing in patients, and Phase III is a very large study of efficacy in the intended patient population. Following the successful completion of phase III testing, a New Drug Application is submitted to the FDA. The FDA review the data and if the product is seen as having a positive benefit-risk assessment, approval to market the product in the US is granted.


Question: What type of filing is used before beginning human trials?

Answer: Investigational New Drug

In the United States, new pharmaceutical products must be approved by the Food and Drug Administration (FDA) as being both safe and effective. <hl> This process generally involves submission of an Investigational New Drug filing with sufficient pre-clinical data to support proceeding with human trials. <hl> Following IND approval, three phases of progressively larger human clinical trials may be conducted. Phase I generally studies toxicity using healthy volunteers. Phase II can include pharmacokinetics and dosing in patients, and Phase III is a very large study of efficacy in the intended patient population. Following the successful completion of phase III testing, a New Drug Application is submitted to the FDA. The FDA review the data and if the product is seen as having a positive benefit-risk assessment, approval to market the product in the US is granted.

In the United States, new pharmaceutical products must be approved by the Food and Drug Administration (FDA) as being both safe and effective. This process generally involves submission of an <hl> Investigational New Drug <hl> filing with sufficient pre-clinical data to support proceeding with human trials. Following IND approval, three phases of progressively larger human clinical trials may be conducted. Phase I generally studies toxicity using healthy volunteers. Phase II can include pharmacokinetics and dosing in patients, and Phase III is a very large study of efficacy in the intended patient population. Following the successful completion of phase III testing, a New Drug Application is submitted to the FDA. The FDA review the data and if the product is seen as having a positive benefit-risk assessment, approval to market the product in the US is granted.


Question: How many phases of human trials may be done after IND approval?

Answer: three

In the United States, new pharmaceutical products must be approved by the Food and Drug Administration (FDA) as being both safe and effective. This process generally involves submission of an Investigational New Drug filing with sufficient pre-clinical data to support proceeding with human trials. <hl> Following IND approval, three phases of progressively larger human clinical trials may be conducted. <hl> Phase I generally studies toxicity using healthy volunteers. Phase II can include pharmacokinetics and dosing in patients, and Phase III is a very large study of efficacy in the intended patient population. Following the successful completion of phase III testing, a New Drug Application is submitted to the FDA. The FDA review the data and if the product is seen as having a positive benefit-risk assessment, approval to market the product in the US is granted.

In the United States, new pharmaceutical products must be approved by the Food and Drug Administration (FDA) as being both safe and effective. This process generally involves submission of an Investigational New Drug filing with sufficient pre-clinical data to support proceeding with human trials. Following IND approval, <hl> three <hl> phases of progressively larger human clinical trials may be conducted. Phase I generally studies toxicity using healthy volunteers. Phase II can include pharmacokinetics and dosing in patients, and Phase III is a very large study of efficacy in the intended patient population. Following the successful completion of phase III testing, a New Drug Application is submitted to the FDA. The FDA review the data and if the product is seen as having a positive benefit-risk assessment, approval to market the product in the US is granted.


Question: What type of application is filed after completing three phases of human trials?

Answer: New Drug Application

In the United States, new pharmaceutical products must be approved by the Food and Drug Administration (FDA) as being both safe and effective. This process generally involves submission of an Investigational New Drug filing with sufficient pre-clinical data to support proceeding with human trials. Following IND approval, three phases of progressively larger human clinical trials may be conducted. Phase I generally studies toxicity using healthy volunteers. Phase II can include pharmacokinetics and dosing in patients, and Phase III is a very large study of efficacy in the intended patient population. <hl> Following the successful completion of phase III testing, a New Drug Application is submitted to the FDA. <hl> The FDA review the data and if the product is seen as having a positive benefit-risk assessment, approval to market the product in the US is granted.

In the United States, new pharmaceutical products must be approved by the Food and Drug Administration (FDA) as being both safe and effective. This process generally involves submission of an Investigational New Drug filing with sufficient pre-clinical data to support proceeding with human trials. Following IND approval, three phases of progressively larger human clinical trials may be conducted. Phase I generally studies toxicity using healthy volunteers. Phase II can include pharmacokinetics and dosing in patients, and Phase III is a very large study of efficacy in the intended patient population. Following the successful completion of phase III testing, a <hl> New Drug Application <hl> is submitted to the FDA. The FDA review the data and if the product is seen as having a positive benefit-risk assessment, approval to market the product in the US is granted.


Question: What type of risk assessment results in approving the drug to go on the market?

Answer: positive benefit-risk

In the United States, new pharmaceutical products must be approved by the Food and Drug Administration (FDA) as being both safe and effective. This process generally involves submission of an Investigational New Drug filing with sufficient pre-clinical data to support proceeding with human trials. Following IND approval, three phases of progressively larger human clinical trials may be conducted. Phase I generally studies toxicity using healthy volunteers. Phase II can include pharmacokinetics and dosing in patients, and Phase III is a very large study of efficacy in the intended patient population. Following the successful completion of phase III testing, a New Drug Application is submitted to the FDA. <hl> The FDA review the data and if the product is seen as having a positive benefit-risk assessment, approval to market the product in the US is granted. <hl>

In the United States, new pharmaceutical products must be approved by the Food and Drug Administration (FDA) as being both safe and effective. This process generally involves submission of an Investigational New Drug filing with sufficient pre-clinical data to support proceeding with human trials. Following IND approval, three phases of progressively larger human clinical trials may be conducted. Phase I generally studies toxicity using healthy volunteers. Phase II can include pharmacokinetics and dosing in patients, and Phase III is a very large study of efficacy in the intended patient population. Following the successful completion of phase III testing, a New Drug Application is submitted to the FDA. The FDA review the data and if the product is seen as having a <hl> positive benefit-risk <hl> assessment, approval to market the product in the US is granted.


Question: "Drug reps" are usually hired by what type of firms?

Advertising is common in healthcare journals as well as through more mainstream media routes. In some countries, notably the US, they are allowed to advertise directly to the general public. Pharmaceutical companies generally employ sales people (often called 'drug reps' or, an older term, 'detail men') to market directly and personally to physicians and other healthcare providers. In some countries, notably the US, pharmaceutical companies also employ lobbyists to influence politicians. Marketing of prescription drugs in the US is regulated by the federal Prescription Drug Marketing Act of 1987.

Answer: Pharmaceutical companies

Advertising is common in healthcare journals as well as through more mainstream media routes. In some countries, notably the US, they are allowed to advertise directly to the general public. <hl> Pharmaceutical companies generally employ sales people (often called 'drug reps' or, an older term, 'detail men') to market directly and personally to physicians and other healthcare providers. <hl> In some countries, notably the US, pharmaceutical companies also employ lobbyists to influence politicians. Marketing of prescription drugs in the US is regulated by the federal Prescription Drug Marketing Act of 1987.

Advertising is common in healthcare journals as well as through more mainstream media routes. In some countries, notably the US, they are allowed to advertise directly to the general public. <hl> Pharmaceutical companies <hl> generally employ sales people (often called 'drug reps' or, an older term, 'detail men') to market directly and personally to physicians and other healthcare providers. In some countries, notably the US, pharmaceutical companies also employ lobbyists to influence politicians. Marketing of prescription drugs in the US is regulated by the federal Prescription Drug Marketing Act of 1987.


Question: What law regulates drug marketing in the US?

Answer: Prescription Drug Marketing Act of 1987

Advertising is common in healthcare journals as well as through more mainstream media routes. In some countries, notably the US, they are allowed to advertise directly to the general public. Pharmaceutical companies generally employ sales people (often called 'drug reps' or, an older term, 'detail men') to market directly and personally to physicians and other healthcare providers. In some countries, notably the US, pharmaceutical companies also employ lobbyists to influence politicians. <hl> Marketing of prescription drugs in the US is regulated by the federal Prescription Drug Marketing Act of 1987 . <hl>

Advertising is common in healthcare journals as well as through more mainstream media routes. In some countries, notably the US, they are allowed to advertise directly to the general public. Pharmaceutical companies generally employ sales people (often called 'drug reps' or, an older term, 'detail men') to market directly and personally to physicians and other healthcare providers. In some countries, notably the US, pharmaceutical companies also employ lobbyists to influence politicians. Marketing of prescription drugs in the US is regulated by the federal <hl> Prescription Drug Marketing Act of 1987 <hl>.

Marketing of prescription drugs in the US is regulated by the federal <hl> Prescription Drug Marketing Act of 1987 <hl> .


Question: Who do drug reps market to?

Answer: directly and personally to physicians

Advertising is common in healthcare journals as well as through more mainstream media routes. In some countries, notably the US, they are allowed to advertise directly to the general public. <hl> Pharmaceutical companies generally employ sales people (often called 'drug reps' or, an older term, 'detail men') to market directly and personally to physicians and other healthcare providers. <hl> In some countries, notably the US, pharmaceutical companies also employ lobbyists to influence politicians. Marketing of prescription drugs in the US is regulated by the federal Prescription Drug Marketing Act of 1987.

Advertising is common in healthcare journals as well as through more mainstream media routes. In some countries, notably the US, they are allowed to advertise directly to the general public. Pharmaceutical companies generally employ sales people (often called 'drug reps' or, an older term, 'detail men') to market <hl> directly and personally to physicians <hl> and other healthcare providers. In some countries, notably the US, pharmaceutical companies also employ lobbyists to influence politicians. Marketing of prescription drugs in the US is regulated by the federal Prescription Drug Marketing Act of 1987.


Question: Drug reps have been accused of giving what to health professionals?

There has been increasing controversy surrounding pharmaceutical marketing and influence. There have been accusations and findings of influence on doctors and other health professionals through drug reps, including the constant provision of marketing 'gifts' and biased information to health professionals; highly prevalent advertising in journals and conferences; funding independent healthcare organizations and health promotion campaigns; lobbying physicians and politicians (more than any other industry in the US); sponsorship of medical schools or nurse training; sponsorship of continuing educational events, with influence on the curriculum; and hiring physicians as paid consultants on medical advisory boards.

Answer: 'gifts' and biased information

There has been increasing controversy surrounding pharmaceutical marketing and influence. <hl> There have been accusations and findings of influence on doctors and other health professionals through drug reps, including the constant provision of marketing 'gifts' and biased information to health professionals; highly prevalent advertising in journals and conferences; funding independent healthcare organizations and health promotion campaigns; lobbying physicians and politicians (more than any other industry in the US); sponsorship of medical schools or nurse training; sponsorship of continuing educational events, with influence on the curriculum; and hiring physicians as paid consultants on medical advisory boards. <hl>

There has been increasing controversy surrounding pharmaceutical marketing and influence. There have been accusations and findings of influence on doctors and other health professionals through drug reps, including the constant provision of marketing <hl> 'gifts' and biased information <hl> to health professionals; highly prevalent advertising in journals and conferences; funding independent healthcare organizations and health promotion campaigns; lobbying physicians and politicians (more than any other industry in the US); sponsorship of medical schools or nurse training; sponsorship of continuing educational events, with influence on the curriculum; and hiring physicians as paid consultants on medical advisory boards.


Question: Drug marketers have hired who as paid consultants?

Answer: physicians

There has been increasing controversy surrounding pharmaceutical marketing and influence. <hl> There have been accusations and findings of influence on doctors and other health professionals through drug reps, including the constant provision of marketing 'gifts' and biased information to health professionals; highly prevalent advertising in journals and conferences; funding independent healthcare organizations and health promotion campaigns; lobbying physicians and politicians (more than any other industry in the US); sponsorship of medical schools or nurse training; sponsorship of continuing educational events, with influence on the curriculum; and hiring physicians as paid consultants on medical advisory boards. <hl>

There has been increasing controversy surrounding pharmaceutical marketing and influence. There have been accusations and findings of influence on doctors and other health professionals through drug reps, including the constant provision of marketing 'gifts' and biased information to health professionals; highly prevalent advertising in journals and conferences; funding independent healthcare organizations and health promotion campaigns; lobbying <hl> physicians <hl> and politicians (more than any other industry in the US); sponsorship of medical schools or nurse training; sponsorship of continuing educational events, with influence on the curriculum; and hiring physicians as paid consultants on medical advisory boards.


Question: What publications can drug ads be commonly found?

Answer: journals and conferences

There has been increasing controversy surrounding pharmaceutical marketing and influence. <hl> There have been accusations and findings of influence on doctors and other health professionals through drug reps, including the constant provision of marketing 'gifts' and biased information to health professionals; highly prevalent advertising in journals and conferences ; funding independent healthcare organizations and health promotion campaigns; lobbying physicians and politicians (more than any other industry in the US); sponsorship of medical schools or nurse training; sponsorship of continuing educational events, with influence on the curriculum; and hiring physicians as paid consultants on medical advisory boards. <hl>

There has been increasing controversy surrounding pharmaceutical marketing and influence. There have been accusations and findings of influence on doctors and other health professionals through drug reps, including the constant provision of marketing 'gifts' and biased information to health professionals; highly prevalent advertising in <hl> journals and conferences <hl>; funding independent healthcare organizations and health promotion campaigns; lobbying physicians and politicians (more than any other industry in the US); sponsorship of medical schools or nurse training; sponsorship of continuing educational events, with influence on the curriculum; and hiring physicians as paid consultants on medical advisory boards.

There have been accusations and findings of influence on doctors and other health professionals through drug reps, including the constant provision of marketing 'gifts' and biased information to health professionals; highly prevalent advertising in <hl> journals and conferences <hl> ; funding independent healthcare organizations and health promotion campaigns; lobbying physicians and politicians (more than any other industry in the US); sponsorship of medical schools or nurse training; sponsorship of continuing educational events, with influence on the curriculum; and hiring physicians as paid consultants on medical advisory boards.


Question: In what year CE did the Second Muslim Civil War end?

The rivalries between the Arab tribes had caused unrest in the provinces outside Syria, most notably in the Second Muslim Civil War of 680–692 CE and the Berber Revolt of 740–743 CE. During the Second Civil War, leadership of the Umayyad clan shifted from the Sufyanid branch of the family to the Marwanid branch. As the constant campaigning exhausted the resources and manpower of the state, the Umayyads, weakened by the Third Muslim Civil War of 744–747 CE, were finally toppled by the Abbasid Revolution in 750 CE/132 AH. A branch of the family fled across North Africa to Al-Andalus, where they established the Caliphate of Córdoba, which lasted until 1031 before falling due to the Fitna of al-Ándalus.

Answer: 692

<hl> The rivalries between the Arab tribes had caused unrest in the provinces outside Syria, most notably in the Second Muslim Civil War of 680– 692 CE and the Berber Revolt of 740–743 CE. <hl> During the Second Civil War, leadership of the Umayyad clan shifted from the Sufyanid branch of the family to the Marwanid branch. As the constant campaigning exhausted the resources and manpower of the state, the Umayyads, weakened by the Third Muslim Civil War of 744–747 CE, were finally toppled by the Abbasid Revolution in 750 CE/132 AH. A branch of the family fled across North Africa to Al-Andalus, where they established the Caliphate of Córdoba, which lasted until 1031 before falling due to the Fitna of al-Ándalus.

The rivalries between the Arab tribes had caused unrest in the provinces outside Syria, most notably in the Second Muslim Civil War of 680–<hl> 692 <hl> CE and the Berber Revolt of 740–743 CE. During the Second Civil War, leadership of the Umayyad clan shifted from the Sufyanid branch of the family to the Marwanid branch. As the constant campaigning exhausted the resources and manpower of the state, the Umayyads, weakened by the Third Muslim Civil War of 744–747 CE, were finally toppled by the Abbasid Revolution in 750 CE/132 AH. A branch of the family fled across North Africa to Al-Andalus, where they established the Caliphate of Córdoba, which lasted until 1031 before falling due to the Fitna of al-Ándalus.

The rivalries between the Arab tribes had caused unrest in the provinces outside Syria, most notably in the Second Muslim Civil War of 680– <hl> 692 <hl> CE and the Berber Revolt of 740–743 CE.


Question: During what period did the Berber Revolt occur?

Answer: 740–743 CE

<hl> The rivalries between the Arab tribes had caused unrest in the provinces outside Syria, most notably in the Second Muslim Civil War of 680–692 CE and the Berber Revolt of 740–743 CE . <hl> During the Second Civil War, leadership of the Umayyad clan shifted from the Sufyanid branch of the family to the Marwanid branch. As the constant campaigning exhausted the resources and manpower of the state, the Umayyads, weakened by the Third Muslim Civil War of 744–747 CE, were finally toppled by the Abbasid Revolution in 750 CE/132 AH. A branch of the family fled across North Africa to Al-Andalus, where they established the Caliphate of Córdoba, which lasted until 1031 before falling due to the Fitna of al-Ándalus.

The rivalries between the Arab tribes had caused unrest in the provinces outside Syria, most notably in the Second Muslim Civil War of 680–692 CE and the Berber Revolt of <hl> 740–743 CE <hl>. During the Second Civil War, leadership of the Umayyad clan shifted from the Sufyanid branch of the family to the Marwanid branch. As the constant campaigning exhausted the resources and manpower of the state, the Umayyads, weakened by the Third Muslim Civil War of 744–747 CE, were finally toppled by the Abbasid Revolution in 750 CE/132 AH. A branch of the family fled across North Africa to Al-Andalus, where they established the Caliphate of Córdoba, which lasted until 1031 before falling due to the Fitna of al-Ándalus.

The rivalries between the Arab tribes had caused unrest in the provinces outside Syria, most notably in the Second Muslim Civil War of 680–692 CE and the Berber Revolt of <hl> 740–743 CE <hl> .


Question: What branch took over Umayyad leadership during the Second Civil War?

Answer: Marwanid

The rivalries between the Arab tribes had caused unrest in the provinces outside Syria, most notably in the Second Muslim Civil War of 680–692 CE and the Berber Revolt of 740–743 CE. <hl> During the Second Civil War, leadership of the Umayyad clan shifted from the Sufyanid branch of the family to the Marwanid branch. <hl> As the constant campaigning exhausted the resources and manpower of the state, the Umayyads, weakened by the Third Muslim Civil War of 744–747 CE, were finally toppled by the Abbasid Revolution in 750 CE/132 AH. A branch of the family fled across North Africa to Al-Andalus, where they established the Caliphate of Córdoba, which lasted until 1031 before falling due to the Fitna of al-Ándalus.

The rivalries between the Arab tribes had caused unrest in the provinces outside Syria, most notably in the Second Muslim Civil War of 680–692 CE and the Berber Revolt of 740–743 CE. During the Second Civil War, leadership of the Umayyad clan shifted from the Sufyanid branch of the family to the <hl> Marwanid <hl> branch. As the constant campaigning exhausted the resources and manpower of the state, the Umayyads, weakened by the Third Muslim Civil War of 744–747 CE, were finally toppled by the Abbasid Revolution in 750 CE/132 AH. A branch of the family fled across North Africa to Al-Andalus, where they established the Caliphate of Córdoba, which lasted until 1031 before falling due to the Fitna of al-Ándalus.


Question: In what year was Ali killed?

Ali was assassinated in 661 by a Kharijite partisan. Six months later in the same year, in the interest of peace, Hasan ibn Ali, highly regarded for his wisdom and as a peacemaker, and the Second Imam for the Shias, and the grandson of Muhammad, made a peace treaty with Muawiyah I. In the Hasan-Muawiya treaty, Hasan ibn Ali handed over power to Muawiya on the condition that he be just to the people and keep them safe and secure, and after his death he not establish a dynasty. This brought to an end the era of the Rightly Guided Caliphs for the Sunnis, and Hasan ibn Ali was also the last Imam for the Shias to be a Caliph. Following this, Mu'awiyah broke the conditions of the agreement and began the Umayyad dynasty, with its capital in Damascus.

Answer: 661

<hl> Ali was assassinated in 661 by a Kharijite partisan. <hl> Six months later in the same year, in the interest of peace, Hasan ibn Ali, highly regarded for his wisdom and as a peacemaker, and the Second Imam for the Shias, and the grandson of Muhammad, made a peace treaty with Muawiyah I. In the Hasan-Muawiya treaty, Hasan ibn Ali handed over power to Muawiya on the condition that he be just to the people and keep them safe and secure, and after his death he not establish a dynasty. This brought to an end the era of the Rightly Guided Caliphs for the Sunnis, and Hasan ibn Ali was also the last Imam for the Shias to be a Caliph. Following this, Mu'awiyah broke the conditions of the agreement and began the Umayyad dynasty, with its capital in Damascus.

Ali was assassinated in <hl> 661 <hl> by a Kharijite partisan. Six months later in the same year, in the interest of peace, Hasan ibn Ali, highly regarded for his wisdom and as a peacemaker, and the Second Imam for the Shias, and the grandson of Muhammad, made a peace treaty with Muawiyah I. In the Hasan-Muawiya treaty, Hasan ibn Ali handed over power to Muawiya on the condition that he be just to the people and keep them safe and secure, and after his death he not establish a dynasty. This brought to an end the era of the Rightly Guided Caliphs for the Sunnis, and Hasan ibn Ali was also the last Imam for the Shias to be a Caliph. Following this, Mu'awiyah broke the conditions of the agreement and began the Umayyad dynasty, with its capital in Damascus.


Question: Who killed Ali?

Answer: Kharijite partisan

<hl> Ali was assassinated in 661 by a Kharijite partisan . <hl> Six months later in the same year, in the interest of peace, Hasan ibn Ali, highly regarded for his wisdom and as a peacemaker, and the Second Imam for the Shias, and the grandson of Muhammad, made a peace treaty with Muawiyah I. In the Hasan-Muawiya treaty, Hasan ibn Ali handed over power to Muawiya on the condition that he be just to the people and keep them safe and secure, and after his death he not establish a dynasty. This brought to an end the era of the Rightly Guided Caliphs for the Sunnis, and Hasan ibn Ali was also the last Imam for the Shias to be a Caliph. Following this, Mu'awiyah broke the conditions of the agreement and began the Umayyad dynasty, with its capital in Damascus.

Ali was assassinated in 661 by a <hl> Kharijite partisan <hl>. Six months later in the same year, in the interest of peace, Hasan ibn Ali, highly regarded for his wisdom and as a peacemaker, and the Second Imam for the Shias, and the grandson of Muhammad, made a peace treaty with Muawiyah I. In the Hasan-Muawiya treaty, Hasan ibn Ali handed over power to Muawiya on the condition that he be just to the people and keep them safe and secure, and after his death he not establish a dynasty. This brought to an end the era of the Rightly Guided Caliphs for the Sunnis, and Hasan ibn Ali was also the last Imam for the Shias to be a Caliph. Following this, Mu'awiyah broke the conditions of the agreement and began the Umayyad dynasty, with its capital in Damascus.

Ali was assassinated in 661 by a <hl> Kharijite partisan <hl> .


Question: Who made peace with Muawiyah I?

Answer: Hasan ibn Ali

Ali was assassinated in 661 by a Kharijite partisan. <hl> Six months later in the same year, in the interest of peace, Hasan ibn Ali , highly regarded for his wisdom and as a peacemaker, and the Second Imam for the Shias, and the grandson of Muhammad, made a peace treaty with Muawiyah I. <hl> In the Hasan-Muawiya treaty, Hasan ibn Ali handed over power to Muawiya on the condition that he be just to the people and keep them safe and secure, and after his death he not establish a dynasty. This brought to an end the era of the Rightly Guided Caliphs for the Sunnis, and Hasan ibn Ali was also the last Imam for the Shias to be a Caliph. Following this, Mu'awiyah broke the conditions of the agreement and began the Umayyad dynasty, with its capital in Damascus.

Ali was assassinated in 661 by a Kharijite partisan. Six months later in the same year, in the interest of peace, <hl> Hasan ibn Ali <hl>, highly regarded for his wisdom and as a peacemaker, and the Second Imam for the Shias, and the grandson of Muhammad, made a peace treaty with Muawiyah I. In the Hasan-Muawiya treaty, Hasan ibn Ali handed over power to Muawiya on the condition that he be just to the people and keep them safe and secure, and after his death he not establish a dynasty. This brought to an end the era of the Rightly Guided Caliphs for the Sunnis, and Hasan ibn Ali was also the last Imam for the Shias to be a Caliph. Following this, Mu'awiyah broke the conditions of the agreement and began the Umayyad dynasty, with its capital in Damascus.

Six months later in the same year, in the interest of peace, <hl> Hasan ibn Ali <hl> , highly regarded for his wisdom and as a peacemaker, and the Second Imam for the Shias, and the grandson of Muhammad, made a peace treaty with Muawiyah I.


Question: Where was the capital of the Umayyad dynasty?

Answer: Damascus

Ali was assassinated in 661 by a Kharijite partisan. Six months later in the same year, in the interest of peace, Hasan ibn Ali, highly regarded for his wisdom and as a peacemaker, and the Second Imam for the Shias, and the grandson of Muhammad, made a peace treaty with Muawiyah I. In the Hasan-Muawiya treaty, Hasan ibn Ali handed over power to Muawiya on the condition that he be just to the people and keep them safe and secure, and after his death he not establish a dynasty. This brought to an end the era of the Rightly Guided Caliphs for the Sunnis, and Hasan ibn Ali was also the last Imam for the Shias to be a Caliph. <hl> Following this, Mu'awiyah broke the conditions of the agreement and began the Umayyad dynasty, with its capital in Damascus . <hl>

Ali was assassinated in 661 by a Kharijite partisan. Six months later in the same year, in the interest of peace, Hasan ibn Ali, highly regarded for his wisdom and as a peacemaker, and the Second Imam for the Shias, and the grandson of Muhammad, made a peace treaty with Muawiyah I. In the Hasan-Muawiya treaty, Hasan ibn Ali handed over power to Muawiya on the condition that he be just to the people and keep them safe and secure, and after his death he not establish a dynasty. This brought to an end the era of the Rightly Guided Caliphs for the Sunnis, and Hasan ibn Ali was also the last Imam for the Shias to be a Caliph. Following this, Mu'awiyah broke the conditions of the agreement and began the Umayyad dynasty, with its capital in <hl> Damascus <hl>.

Following this, Mu'awiyah broke the conditions of the agreement and began the Umayyad dynasty, with its capital in <hl> Damascus <hl> .


Question: What form of tax were Christians required to pay?

At the time, the Umayyad taxation and administrative practice were perceived as unjust by some Muslims. The Christian and Jewish population had still autonomy; their judicial matters were dealt with in accordance with their own laws and by their own religious heads or their appointees, although they did pay a poll tax for policing to the central state. Muhammad had stated explicitly during his lifetime that abrahamic religious groups (still a majority in times of the Umayyad Caliphate), should be allowed to practice their own religion, provided that they paid the jizya taxation. The welfare state of both the Muslim and the non-Muslim poor started by Umar ibn al Khattab had also continued. Muawiya's wife Maysum (Yazid's mother) was also a Christian. The relations between the Muslims and the Christians in the state were stable in this time. The Umayyads were involved in frequent battles with the Christian Byzantines without being concerned with protecting themselves in Syria, which had remained largely Christian like many other parts of the empire. Prominent positions were held by Christians, some of whom belonged to families that had served in Byzantine governments. The employment of Christians was part of a broader policy of religious assimilation that was necessitated by the presence of large Christian populations in the conquered provinces, as in Syria. This policy also boosted Muawiya's popularity and solidified Syria as his power base.

Answer: jizya

At the time, the Umayyad taxation and administrative practice were perceived as unjust by some Muslims. The Christian and Jewish population had still autonomy; their judicial matters were dealt with in accordance with their own laws and by their own religious heads or their appointees, although they did pay a poll tax for policing to the central state. <hl> Muhammad had stated explicitly during his lifetime that abrahamic religious groups (still a majority in times of the Umayyad Caliphate), should be allowed to practice their own religion, provided that they paid the jizya taxation. <hl> The welfare state of both the Muslim and the non-Muslim poor started by Umar ibn al Khattab had also continued. Muawiya's wife Maysum (Yazid's mother) was also a Christian. The relations between the Muslims and the Christians in the state were stable in this time. The Umayyads were involved in frequent battles with the Christian Byzantines without being concerned with protecting themselves in Syria, which had remained largely Christian like many other parts of the empire. Prominent positions were held by Christians, some of whom belonged to families that had served in Byzantine governments. The employment of Christians was part of a broader policy of religious assimilation that was necessitated by the presence of large Christian populations in the conquered provinces, as in Syria. This policy also boosted Muawiya's popularity and solidified Syria as his power base.

At the time, the Umayyad taxation and administrative practice were perceived as unjust by some Muslims. The Christian and Jewish population had still autonomy; their judicial matters were dealt with in accordance with their own laws and by their own religious heads or their appointees, although they did pay a poll tax for policing to the central state. Muhammad had stated explicitly during his lifetime that abrahamic religious groups (still a majority in times of the Umayyad Caliphate), should be allowed to practice their own religion, provided that they paid the <hl> jizya <hl> taxation. The welfare state of both the Muslim and the non-Muslim poor started by Umar ibn al Khattab had also continued. Muawiya's wife Maysum (Yazid's mother) was also a Christian. The relations between the Muslims and the Christians in the state were stable in this time. The Umayyads were involved in frequent battles with the Christian Byzantines without being concerned with protecting themselves in Syria, which had remained largely Christian like many other parts of the empire. Prominent positions were held by Christians, some of whom belonged to families that had served in Byzantine governments. The employment of Christians was part of a broader policy of religious assimilation that was necessitated by the presence of large Christian populations in the conquered provinces, as in Syria. This policy also boosted Muawiya's popularity and solidified Syria as his power base.


Question: Who was the mother of Yazid?

Answer: Maysum

At the time, the Umayyad taxation and administrative practice were perceived as unjust by some Muslims. The Christian and Jewish population had still autonomy; their judicial matters were dealt with in accordance with their own laws and by their own religious heads or their appointees, although they did pay a poll tax for policing to the central state. Muhammad had stated explicitly during his lifetime that abrahamic religious groups (still a majority in times of the Umayyad Caliphate), should be allowed to practice their own religion, provided that they paid the jizya taxation. The welfare state of both the Muslim and the non-Muslim poor started by Umar ibn al Khattab had also continued. <hl> Muawiya's wife Maysum (Yazid's mother) was also a Christian. <hl> The relations between the Muslims and the Christians in the state were stable in this time. The Umayyads were involved in frequent battles with the Christian Byzantines without being concerned with protecting themselves in Syria, which had remained largely Christian like many other parts of the empire. Prominent positions were held by Christians, some of whom belonged to families that had served in Byzantine governments. The employment of Christians was part of a broader policy of religious assimilation that was necessitated by the presence of large Christian populations in the conquered provinces, as in Syria. This policy also boosted Muawiya's popularity and solidified Syria as his power base.

At the time, the Umayyad taxation and administrative practice were perceived as unjust by some Muslims. The Christian and Jewish population had still autonomy; their judicial matters were dealt with in accordance with their own laws and by their own religious heads or their appointees, although they did pay a poll tax for policing to the central state. Muhammad had stated explicitly during his lifetime that abrahamic religious groups (still a majority in times of the Umayyad Caliphate), should be allowed to practice their own religion, provided that they paid the jizya taxation. The welfare state of both the Muslim and the non-Muslim poor started by Umar ibn al Khattab had also continued. Muawiya's wife <hl> Maysum <hl> (Yazid's mother) was also a Christian. The relations between the Muslims and the Christians in the state were stable in this time. The Umayyads were involved in frequent battles with the Christian Byzantines without being concerned with protecting themselves in Syria, which had remained largely Christian like many other parts of the empire. Prominent positions were held by Christians, some of whom belonged to families that had served in Byzantine governments. The employment of Christians was part of a broader policy of religious assimilation that was necessitated by the presence of large Christian populations in the conquered provinces, as in Syria. This policy also boosted Muawiya's popularity and solidified Syria as his power base.


Question: What was Maysum's religion?

Answer: Christian

At the time, the Umayyad taxation and administrative practice were perceived as unjust by some Muslims. <hl> The Christian and Jewish population had still autonomy; their judicial matters were dealt with in accordance with their own laws and by their own religious heads or their appointees, although they did pay a poll tax for policing to the central state. <hl> Muhammad had stated explicitly during his lifetime that abrahamic religious groups (still a majority in times of the Umayyad Caliphate), should be allowed to practice their own religion, provided that they paid the jizya taxation. The welfare state of both the Muslim and the non-Muslim poor started by Umar ibn al Khattab had also continued. Muawiya's wife Maysum (Yazid's mother) was also a Christian. The relations between the Muslims and the Christians in the state were stable in this time. The Umayyads were involved in frequent battles with the Christian Byzantines without being concerned with protecting themselves in Syria, which had remained largely Christian like many other parts of the empire. Prominent positions were held by Christians, some of whom belonged to families that had served in Byzantine governments. The employment of Christians was part of a broader policy of religious assimilation that was necessitated by the presence of large Christian populations in the conquered provinces, as in Syria. This policy also boosted Muawiya's popularity and solidified Syria as his power base.

At the time, the Umayyad taxation and administrative practice were perceived as unjust by some Muslims. The <hl> Christian <hl> and Jewish population had still autonomy; their judicial matters were dealt with in accordance with their own laws and by their own religious heads or their appointees, although they did pay a poll tax for policing to the central state. Muhammad had stated explicitly during his lifetime that abrahamic religious groups (still a majority in times of the Umayyad Caliphate), should be allowed to practice their own religion, provided that they paid the jizya taxation. The welfare state of both the Muslim and the non-Muslim poor started by Umar ibn al Khattab had also continued. Muawiya's wife Maysum (Yazid's mother) was also a Christian. The relations between the Muslims and the Christians in the state were stable in this time. The Umayyads were involved in frequent battles with the Christian Byzantines without being concerned with protecting themselves in Syria, which had remained largely Christian like many other parts of the empire. Prominent positions were held by Christians, some of whom belonged to families that had served in Byzantine governments. The employment of Christians was part of a broader policy of religious assimilation that was necessitated by the presence of large Christian populations in the conquered provinces, as in Syria. This policy also boosted Muawiya's popularity and solidified Syria as his power base.


Question: How many major Islamic caliphates existed after Muhammad's death?

The Umayyad Caliphate (Arabic: الخلافة الأموية, trans. Al-Khilāfat al-ʾumawiyya) was the second of the four major Islamic caliphates established after the death of Muhammad. This caliphate was centered on the Umayyad dynasty (Arabic: الأمويون, al-ʾUmawiyyūn, or بنو أمية, Banū ʾUmayya, "Sons of Umayya"), hailing from Mecca. The Umayyad family had first come to power under the third caliph, Uthman ibn Affan (r. 644–656), but the Umayyad regime was founded by Muawiya ibn Abi Sufyan, long-time governor of Syria, after the end of the First Muslim Civil War in 661 CE/41 AH. Syria remained the Umayyads' main power base thereafter, and Damascus was their capital. The Umayyads continued the Muslim conquests, incorporating the Caucasus, Transoxiana, Sindh, the Maghreb and the Iberian Peninsula (Al-Andalus) into the Muslim world. At its greatest extent, the Umayyad Caliphate covered 15 million km2 (5.79 million square miles), making it the largest empire (in terms of area - not in terms of population) the world had yet seen, and the fifth largest ever to exist.

Answer: four

The Umayyad Caliphate (Arabic: الخلافة الأموية, trans. <hl> Al-Khilāfat al-ʾumawiyya) was the second of the four major Islamic caliphates established after the death of Muhammad. <hl> This caliphate was centered on the Umayyad dynasty (Arabic: الأمويون, al-ʾUmawiyyūn, or بنو أمية, Banū ʾUmayya, "Sons of Umayya"), hailing from Mecca. The Umayyad family had first come to power under the third caliph, Uthman ibn Affan (r. 644–656), but the Umayyad regime was founded by Muawiya ibn Abi Sufyan, long-time governor of Syria, after the end of the First Muslim Civil War in 661 CE/41 AH. Syria remained the Umayyads' main power base thereafter, and Damascus was their capital. The Umayyads continued the Muslim conquests, incorporating the Caucasus, Transoxiana, Sindh, the Maghreb and the Iberian Peninsula (Al-Andalus) into the Muslim world. At its greatest extent, the Umayyad Caliphate covered 15 million km2 (5.79 million square miles), making it the largest empire (in terms of area - not in terms of population) the world had yet seen, and the fifth largest ever to exist.

The Umayyad Caliphate (Arabic: الخلافة الأموية, trans. Al-Khilāfat al-ʾumawiyya) was the second of the <hl> four <hl> major Islamic caliphates established after the death of Muhammad. This caliphate was centered on the Umayyad dynasty (Arabic: الأمويون, al-ʾUmawiyyūn, or بنو أمية, Banū ʾUmayya, "Sons of Umayya"), hailing from Mecca. The Umayyad family had first come to power under the third caliph, Uthman ibn Affan (r. 644–656), but the Umayyad regime was founded by Muawiya ibn Abi Sufyan, long-time governor of Syria, after the end of the First Muslim Civil War in 661 CE/41 AH. Syria remained the Umayyads' main power base thereafter, and Damascus was their capital. The Umayyads continued the Muslim conquests, incorporating the Caucasus, Transoxiana, Sindh, the Maghreb and the Iberian Peninsula (Al-Andalus) into the Muslim world. At its greatest extent, the Umayyad Caliphate covered 15 million km2 (5.79 million square miles), making it the largest empire (in terms of area - not in terms of population) the world had yet seen, and the fifth largest ever to exist.


Question: Who was the third caliph?

Answer: Uthman ibn Affan

The Umayyad Caliphate (Arabic: الخلافة الأموية, trans. Al-Khilāfat al-ʾumawiyya) was the second of the four major Islamic caliphates established after the death of Muhammad. This caliphate was centered on the Umayyad dynasty (Arabic: الأمويون, al-ʾUmawiyyūn, or بنو أمية, Banū ʾUmayya, "Sons of Umayya"), hailing from Mecca. <hl> The Umayyad family had first come to power under the third caliph, Uthman ibn Affan (r. 644–656), but the Umayyad regime was founded by Muawiya ibn Abi Sufyan, long-time governor of Syria, after the end of the First Muslim Civil War in 661 CE/41 AH. <hl> Syria remained the Umayyads' main power base thereafter, and Damascus was their capital. The Umayyads continued the Muslim conquests, incorporating the Caucasus, Transoxiana, Sindh, the Maghreb and the Iberian Peninsula (Al-Andalus) into the Muslim world. At its greatest extent, the Umayyad Caliphate covered 15 million km2 (5.79 million square miles), making it the largest empire (in terms of area - not in terms of population) the world had yet seen, and the fifth largest ever to exist.

The Umayyad Caliphate (Arabic: الخلافة الأموية, trans. Al-Khilāfat al-ʾumawiyya) was the second of the four major Islamic caliphates established after the death of Muhammad. This caliphate was centered on the Umayyad dynasty (Arabic: الأمويون, al-ʾUmawiyyūn, or بنو أمية, Banū ʾUmayya, "Sons of Umayya"), hailing from Mecca. The Umayyad family had first come to power under the third caliph, <hl> Uthman ibn Affan <hl> (r. 644–656), but the Umayyad regime was founded by Muawiya ibn Abi Sufyan, long-time governor of Syria, after the end of the First Muslim Civil War in 661 CE/41 AH. Syria remained the Umayyads' main power base thereafter, and Damascus was their capital. The Umayyads continued the Muslim conquests, incorporating the Caucasus, Transoxiana, Sindh, the Maghreb and the Iberian Peninsula (Al-Andalus) into the Muslim world. At its greatest extent, the Umayyad Caliphate covered 15 million km2 (5.79 million square miles), making it the largest empire (in terms of area - not in terms of population) the world had yet seen, and the fifth largest ever to exist.


Question: Who founded the Umayyad regime?

Answer: Muawiya ibn Abi Sufyan

The Umayyad Caliphate (Arabic: الخلافة الأموية, trans. Al-Khilāfat al-ʾumawiyya) was the second of the four major Islamic caliphates established after the death of Muhammad. This caliphate was centered on the Umayyad dynasty (Arabic: الأمويون, al-ʾUmawiyyūn, or بنو أمية, Banū ʾUmayya, "Sons of Umayya"), hailing from Mecca. <hl> The Umayyad family had first come to power under the third caliph, Uthman ibn Affan (r. 644–656), but the Umayyad regime was founded by Muawiya ibn Abi Sufyan , long-time governor of Syria, after the end of the First Muslim Civil War in 661 CE/41 AH. <hl> Syria remained the Umayyads' main power base thereafter, and Damascus was their capital. The Umayyads continued the Muslim conquests, incorporating the Caucasus, Transoxiana, Sindh, the Maghreb and the Iberian Peninsula (Al-Andalus) into the Muslim world. At its greatest extent, the Umayyad Caliphate covered 15 million km2 (5.79 million square miles), making it the largest empire (in terms of area - not in terms of population) the world had yet seen, and the fifth largest ever to exist.

The Umayyad Caliphate (Arabic: الخلافة الأموية, trans. Al-Khilāfat al-ʾumawiyya) was the second of the four major Islamic caliphates established after the death of Muhammad. This caliphate was centered on the Umayyad dynasty (Arabic: الأمويون, al-ʾUmawiyyūn, or بنو أمية, Banū ʾUmayya, "Sons of Umayya"), hailing from Mecca. The Umayyad family had first come to power under the third caliph, Uthman ibn Affan (r. 644–656), but the Umayyad regime was founded by <hl> Muawiya ibn Abi Sufyan <hl>, long-time governor of Syria, after the end of the First Muslim Civil War in 661 CE/41 AH. Syria remained the Umayyads' main power base thereafter, and Damascus was their capital. The Umayyads continued the Muslim conquests, incorporating the Caucasus, Transoxiana, Sindh, the Maghreb and the Iberian Peninsula (Al-Andalus) into the Muslim world. At its greatest extent, the Umayyad Caliphate covered 15 million km2 (5.79 million square miles), making it the largest empire (in terms of area - not in terms of population) the world had yet seen, and the fifth largest ever to exist.

The Umayyad family had first come to power under the third caliph, Uthman ibn Affan (r. 644–656), but the Umayyad regime was founded by <hl> Muawiya ibn Abi Sufyan <hl> , long-time governor of Syria, after the end of the First Muslim Civil War in 661 CE/41 AH.


Question: How many million square miles was the Umayyad caliphate at its largest size?

Answer: 5.79

The Umayyad Caliphate (Arabic: الخلافة الأموية, trans. Al-Khilāfat al-ʾumawiyya) was the second of the four major Islamic caliphates established after the death of Muhammad. This caliphate was centered on the Umayyad dynasty (Arabic: الأمويون, al-ʾUmawiyyūn, or بنو أمية, Banū ʾUmayya, "Sons of Umayya"), hailing from Mecca. The Umayyad family had first come to power under the third caliph, Uthman ibn Affan (r. 644–656), but the Umayyad regime was founded by Muawiya ibn Abi Sufyan, long-time governor of Syria, after the end of the First Muslim Civil War in 661 CE/41 AH. Syria remained the Umayyads' main power base thereafter, and Damascus was their capital. The Umayyads continued the Muslim conquests, incorporating the Caucasus, Transoxiana, Sindh, the Maghreb and the Iberian Peninsula (Al-Andalus) into the Muslim world. <hl> At its greatest extent, the Umayyad Caliphate covered 15 million km2 ( 5.79 million square miles), making it the largest empire (in terms of area - not in terms of population) <hl> the world had yet seen, and the fifth largest ever to exist.

The Umayyad Caliphate (Arabic: الخلافة الأموية, trans. Al-Khilāfat al-ʾumawiyya) was the second of the four major Islamic caliphates established after the death of Muhammad. This caliphate was centered on the Umayyad dynasty (Arabic: الأمويون, al-ʾUmawiyyūn, or بنو أمية, Banū ʾUmayya, "Sons of Umayya"), hailing from Mecca. The Umayyad family had first come to power under the third caliph, Uthman ibn Affan (r. 644–656), but the Umayyad regime was founded by Muawiya ibn Abi Sufyan, long-time governor of Syria, after the end of the First Muslim Civil War in 661 CE/41 AH. Syria remained the Umayyads' main power base thereafter, and Damascus was their capital. The Umayyads continued the Muslim conquests, incorporating the Caucasus, Transoxiana, Sindh, the Maghreb and the Iberian Peninsula (Al-Andalus) into the Muslim world. At its greatest extent, the Umayyad Caliphate covered 15 million km2 (<hl> 5.79 <hl> million square miles), making it the largest empire (in terms of area - not in terms of population) the world had yet seen, and the fifth largest ever to exist.

At its greatest extent, the Umayyad Caliphate covered 15 million km2 ( <hl> 5.79 <hl> million square miles), making it the largest empire (in terms of area - not in terms of population)


Question: When did Muawiyah become caliph?

Most historians[who?] consider Caliph Muawiyah (661–80) to have been the second ruler of the Umayyad dynasty, even though he was the first to assert the Umayyads' right to rule on a dynastic principle. It was really the caliphate of Uthman Ibn Affan (644–656), a member of Umayyad clan himself, that witnessed the revival and then the ascendancy of the Umayyad clan to the corridors of power. Uthman placed some of the trusted members of his clan at prominent and strong positions throughout the state. Most notable was the appointment of Marwan ibn al-Hakam, Uthman's first cousin, as his top advisor, which created a stir among the Hashimite companions of Muhammad, as Marwan along with his father Al-Hakam ibn Abi al-'As had been permanently exiled from Medina by Muhammad during his lifetime. Uthman also appointed as governor of Kufa his half-brother, Walid ibn Uqba, who was accused by Hashmites of leading prayer while under the influence of alcohol. Uthman also consolidated Muawiyah's governorship of Syria by granting him control over a larger area and appointed his foster brother Abdullah ibn Saad as the Governor of Egypt. However, since Uthman never named an heir, he cannot be considered the founder of a dynasty.

Answer: 661

<hl> Most historians[who?] consider Caliph Muawiyah ( 661 –80) to have been the second ruler of the Umayyad dynasty, even though he was the first to assert the Umayyads' right to rule on a dynastic principle. <hl> It was really the caliphate of Uthman Ibn Affan (644–656), a member of Umayyad clan himself, that witnessed the revival and then the ascendancy of the Umayyad clan to the corridors of power. Uthman placed some of the trusted members of his clan at prominent and strong positions throughout the state. Most notable was the appointment of Marwan ibn al-Hakam, Uthman's first cousin, as his top advisor, which created a stir among the Hashimite companions of Muhammad, as Marwan along with his father Al-Hakam ibn Abi al-'As had been permanently exiled from Medina by Muhammad during his lifetime. Uthman also appointed as governor of Kufa his half-brother, Walid ibn Uqba, who was accused by Hashmites of leading prayer while under the influence of alcohol. Uthman also consolidated Muawiyah's governorship of Syria by granting him control over a larger area and appointed his foster brother Abdullah ibn Saad as the Governor of Egypt. However, since Uthman never named an heir, he cannot be considered the founder of a dynasty.

Most historians[who?] consider Caliph Muawiyah (<hl> 661 <hl>–80) to have been the second ruler of the Umayyad dynasty, even though he was the first to assert the Umayyads' right to rule on a dynastic principle. It was really the caliphate of Uthman Ibn Affan (644–656), a member of Umayyad clan himself, that witnessed the revival and then the ascendancy of the Umayyad clan to the corridors of power. Uthman placed some of the trusted members of his clan at prominent and strong positions throughout the state. Most notable was the appointment of Marwan ibn al-Hakam, Uthman's first cousin, as his top advisor, which created a stir among the Hashimite companions of Muhammad, as Marwan along with his father Al-Hakam ibn Abi al-'As had been permanently exiled from Medina by Muhammad during his lifetime. Uthman also appointed as governor of Kufa his half-brother, Walid ibn Uqba, who was accused by Hashmites of leading prayer while under the influence of alcohol. Uthman also consolidated Muawiyah's governorship of Syria by granting him control over a larger area and appointed his foster brother Abdullah ibn Saad as the Governor of Egypt. However, since Uthman never named an heir, he cannot be considered the founder of a dynasty.

Most historians[who?] consider Caliph Muawiyah ( <hl> 661 <hl> –80) to have been the second ruler of the Umayyad dynasty, even though he was the first to assert the Umayyads' right to rule on a dynastic principle.


Question: When did the caliphate of Uthman Ibn Affan end?

Answer: 656

Most historians[who?] consider Caliph Muawiyah (661–80) to have been the second ruler of the Umayyad dynasty, even though he was the first to assert the Umayyads' right to rule on a dynastic principle. <hl> It was really the caliphate of Uthman Ibn Affan (644– 656 ), a member of Umayyad clan himself, that witnessed the revival and then the ascendancy of the Umayyad clan to the corridors of power. <hl> Uthman placed some of the trusted members of his clan at prominent and strong positions throughout the state. Most notable was the appointment of Marwan ibn al-Hakam, Uthman's first cousin, as his top advisor, which created a stir among the Hashimite companions of Muhammad, as Marwan along with his father Al-Hakam ibn Abi al-'As had been permanently exiled from Medina by Muhammad during his lifetime. Uthman also appointed as governor of Kufa his half-brother, Walid ibn Uqba, who was accused by Hashmites of leading prayer while under the influence of alcohol. Uthman also consolidated Muawiyah's governorship of Syria by granting him control over a larger area and appointed his foster brother Abdullah ibn Saad as the Governor of Egypt. However, since Uthman never named an heir, he cannot be considered the founder of a dynasty.

Most historians[who?] consider Caliph Muawiyah (661–80) to have been the second ruler of the Umayyad dynasty, even though he was the first to assert the Umayyads' right to rule on a dynastic principle. It was really the caliphate of Uthman Ibn Affan (644–<hl> 656 <hl>), a member of Umayyad clan himself, that witnessed the revival and then the ascendancy of the Umayyad clan to the corridors of power. Uthman placed some of the trusted members of his clan at prominent and strong positions throughout the state. Most notable was the appointment of Marwan ibn al-Hakam, Uthman's first cousin, as his top advisor, which created a stir among the Hashimite companions of Muhammad, as Marwan along with his father Al-Hakam ibn Abi al-'As had been permanently exiled from Medina by Muhammad during his lifetime. Uthman also appointed as governor of Kufa his half-brother, Walid ibn Uqba, who was accused by Hashmites of leading prayer while under the influence of alcohol. Uthman also consolidated Muawiyah's governorship of Syria by granting him control over a larger area and appointed his foster brother Abdullah ibn Saad as the Governor of Egypt. However, since Uthman never named an heir, he cannot be considered the founder of a dynasty.

It was really the caliphate of Uthman Ibn Affan (644– <hl> 656 <hl> ), a member of Umayyad clan himself, that witnessed the revival and then the ascendancy of the Umayyad clan to the corridors of power.